HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideLeo Luznik, Ephraim J. Fuchs, Paul V. O’Donnell et al.|Biology of Blood and Marrow Transplantation|2008Cited by 1.9k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Lucio Luzzatto, Neal S. Young et al.|New England Journal of Medicine|2006Cited by 1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A. Brodsky, Peter Hillmen, Neal S. Young et al.|Blood|2007Cited by 653
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaPeter Hillmen, Neal S. Young, Lucio Luzzatto et al.|Blood|2007Cited by 578
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Jennifer A. Kanakry et al.|Blood|2015Cited by 299